Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma

Cancer

Volumn 120, Issue 24, 2014, Pages 3972-3980

  Pérez Larraya, Jaime Gállego ^a,b   Paris, Sophie ^a   Idbaih, Ahmed ^a   Dehais, Caroline ^a   Laigle Donadey, Florence ^a   Navarro, Soledad ^c   Capelle, Laurent ^c   Mokhtari, Karima ^c   Marie, Yannick ^a   Sanson, Marc ^a   Hoang Xuan, Khê ^a   Delattre, Jean Yves ^a   Mallet, Alain ^c  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Biomarkers; Chitinase 3; Glial fibrillary acidic protein (GFAP); Glioblastoma multiforme; Insulin like growth factor binding protein 2 (IGFBP 2); Like protein 1 (YKL 40); Plasma

Indexed keywords

CHITINASE 3 LIKE PROTEIN 1; GLIAL FIBRILLARY ACIDIC PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; TUMOR MARKER; UNCLASSIFIED DRUG; ADIPOCYTOKINE; CHI3L1 PROTEIN, HUMAN; IGFBP-2 PROTEIN, HUMAN; LECTIN;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; HUMAN; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TUMOR DIFFERENTIATION; TUMOR VOLUME; BLOOD; BRAIN NEOPLASMS; MIDDLE AGED; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADIPOKINES; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOBLASTOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; LECTINS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84919329686     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28949     Document Type: Article

References (25)

1. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003.
2. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765-773.
3. Trent JM, Bittner M, Zhang J, et al. Use of microgenomic technology for analysis of alterations in DNA copy number and gene expression in malignant melanoma. Clin Exp Immunol. 1997; 107(suppl 1): 33-40.
4. Sallinen SL, Sallinen PK, Haapasalo HK, et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 2000; 60: 6617-6622.
5. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 2002; 62: 4364-4368.
6. Sampath P, Weaver CE, Sungarian A, Cortez S, Alderson L, Stopa EG. Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma. Cancer Control. 2004; 11: 174-180.
7. Fukuda ME, Iwadate Y, Machida T, et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res. 2005; 65: 5190-5194.
8. Zheng PP, Hop WC, Sillevis Smitt PA, et al. Low-molecular weight caldesmon as a potential serum marker for glioma. Clin Cancer Res. 2005; 11: 4388-4392.
9. Iwamoto FM, Hottinger AF, Karimi S, et al. Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. J Neurooncol. 2011; 105: 607-612.
10. Lin Y, Jiang T, Zhou K, et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol. 2009; 11: 468-476.
11. Hormigo A, Gu B, Karimi S, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res. 2006; 12: 5698-5704.
12. Iwamoto FM, Hottinger AF, Karimi S, et al. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol. 2011; 13: 1244-1251.
13. Bernardi D, Padoan A, Ballin A, et al. Serum YKL-40 following resection for cerebral glioblastoma. J Neurooncol. 2012; 107: 299-305.
14. Jung CS, Foerch C, Schanzer A, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain. 2007; 130: 3336-3341.
15. Brommeland T, Rosengren L, Fridlund S, Hennig R, Isaksen V. Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Scand. 2007; 116: 380-384.
16. Ilhan-Mutlu A, Wagner L, Widhalm G, et al. Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurg Rev. 2013; 36: 45-55; discussion 55-56.
17. Husain H, Savage W, Grossman SA, et al. Pre- and post-operative plasma GFAP levels in patients with newly diagnosed gliomas. J Neurooncol. 2012; 109: 123-127.
18. Kothari RU, Brott T, Broderick JP, et al. The ABCs of measuring intracerebral hemorrhage volumes. Stroke. 1996; 27: 1304-1305.
19. Fischer W, Heller T, Herrmann E, Schreiber D. A simple method for the isolation of GFAP and its use for the study of brain tumors [article in German]. Zentralbl Allg Pathol. 1989; 135: 33-41.
20. Oh D, Prayson RA. Evaluation of epithelial and keratin markers in glioblastoma multiforme: an immunohistochemical study. Arch Pathol Lab Med. 1999; 123: 917-920.
21. Foerch C, Curdt I, Yan B, et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry. 2006; 77: 181-184.
22. Herrmann M, Ehrenreich H. Brain derived proteins as markers of acute stroke: their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor Neurol Neurosci. 2003; 21: 177-190.
23. Pelinka LE, Kroepfl A, Schmidhammer R, et al. Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma. 2004; 57: 1006-1012.
24. Mehrian-Shai R, Chen CD, Shi T, et al. Insulin growth factorbinding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA. 2007; 104: 5563-5568.
25. Dunlap SM, Celestino J, Wang H, et al. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA. 2007; 104: 11736-11741.